Yao YY, Zhu Q, Zou LF, Dou HJ, Chen YM, Tang Y, Hu JP
[Clinical study on fludarabin combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia.] [English Abstract, Journal Article]
Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009 Jun; 17(3):774-6.
The aim of study was to evaluate the clinical efficacy and toxicity of fludarabin combined with cytarabine (FA) regimen in the treatment of patients with refactory and/or relapsed acute myeloid leukemia (AML). Nineteen cases with refactory/relapsed AML were treated with FA regimen in which fludarabine phosphate 25 mg/(m(2)xd), d1-5; cytarabine (Ara-C) 2 g/(m(2)xd), d1-5. Another 20 cases were treated with salvage chemotherapy (MAE regimen: mitoxantrone, Ara-C and etoposide or DAE regimen: daunorubicin, Ara-C and etoposide). All patients received at least 2 cycles chemotherapy. The results showed that 9 patients (47%) in FA regimen group achieved complete remission (CR), 8 cases (42%) obtained partial remission (PR), the clinical efficacy was superior to that of the MAE or DAE regemins (p < 0.05). Major toxicity of FA regimen was myelosuppression. Grade IV hematologic toxicity occrrred in all patients received FA regimen. Nonhematologic complications consisted of gastrointestinal side effects, mucositis, liver toxicity, which were mild to moderate and could be alleviated with supportive therapy. In conclusion, FA regimen is an effective regimen for treatment of refactory and relapsed AML.
More from this journal |
